IP Library Granted Patent US 9,920,112
Granted Patent B2
US 9,920,112 · App. 14/061,080 · Granted Mar 20, 2018

Immunoglobulin-binding proteins with improved specificity

Inventor: Shari Spector (Lexington, MA)
Assignee: EMD Millipore Corporation
C07K16/1271B01J20/286B01J20/3274C07K1/22C07K14/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,920,112
App. No.
14/061,080
Granted
Mar 20, 2018
Kind
B2
Abstract

The present invention relates to modified immunoglobulin-binding proteins, e.g., Staphylococcus protein A, having improved binding specificity for immunoglobulins and methods of making and using the same.

Claims (11)

1. A method of affinity purifying one or more immunoglobulins from a sample, the method comprising the steps of:

(a) providing a sample comprising one or more immunoglobulins;

contacting the sample with a chromatography matrix under conditions such that the one or more immunoglobulins bind to the matrix, wherein the chromatography matrix comprises an immunoglobulin-binding protein which binds an Fc portion of the one or more immunoglobulins but exhibits reduced binding to a Fab portion of the one or more immunoglobulins relative to wild-type protein A and comprises one or more isolated domains comprising the amino acid sequence set forth in SEQ ID NO:10, SEQ ID NO:11 or SEQ ID NO:12, and wherein the one or more isolated domains comprise: (i) at least the glycine residue at position 29 of SEQ ID NO: 10 replaced with an amino acid residue selected from the group consisting of a lysine residue, a leucine residue and an arginine residue, as shown in SEQ ID NO: 23, SEQ ID NO: 24 and SEQ ID NO: 25, respectively; or (ii) at least the glycine residue at position 29 of SEQ ID NO: 11 replaced with an amino acid residue selected from the group consisting of a lysine residue, a leucine residue and an arginine residue, as shown in SEQ ID NO:26, SEQ ID NO: 27 and SEQ ID NO: 28, respectively; or (iii) at least the alanine at position 29 of SEQ ID NO:12 replaced with an amino acid residue selected from the group consisting of a lysine residue, a leucine residue and an arginine residue, as shown in SEQ ID NO: 29, SEQ ID NO: 30 and SEQ ID NO: 31, respectively, and

(b) recovering the one or more bound immunoglobulins by eluting under suitable conditions.

2. The method of claim 1 , wherein the one or more immunoglobulins is selected from the group consisting of IgG, IgA or IgM, or a fragment thereof.

3. The method of claim 1 , wherein the one or more immunoglobulins is an IgG or a fragment thereof.

4. The method of claim 1 , wherein the Fc portion of an immunoglobulin is part of an Fc fusion protein.

5. The method of claim 1 , wherein the amino acid residue is lysine.

6. The method of claim 1 , wherein the immunoglobulin-binding protein is coupled to a solid support.

7. The method of claim 6 , wherein the solid support is selected from the group consisting of controlled pore glass, agarose, methacrylate, and polystyrene.

8. The method of claim 1 , wherein the immunoglobulin-binding protein further comprising at least a portion of the carboxy-terminal region of Staphylococcus protein A.

Assignments (1)
CHANGE OF ADDRESS Recorded Feb 15, 2018
From: EMD MILLIPORE CORPORATION
To: EMD MILLIPORE CORPORATION
Reel/Frame 045341/0166 →
Continuity (4)
Continuation 12462484 · Aug 4, 2009
Provisional Application 61212812 · Apr 16, 2009
Provisional Application 61188549 · Aug 11, 2008
Related Publication 20140046037A1 · Feb 13, 2014